Inactivation of Mirk/Dyrk1b kinase targets quiescent pancreatic cancer cells

Molecular Cancer Therapeutics

Volumn 10, Issue 11, 2011, Pages 2104-2114

  Ewton, Daina Z ^a   Hu, Jing ^a   Vilenchik, Maria ^b   Deng, Xiaobing ^a   Luk, Kin Chun ^b   Polonskaia, Ann ^b   Hoffman, Ann F ^b   Zipf, Karen ^b   Boylan, John F ^b   Friedman, Eileen A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; GEMCITABINE; HISTONE H2AX; MIRK KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; DRUG SENSITIVITY; DRUG SPECIFICITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; DNA DAMAGE; DRUG SYNERGISM; EXONS; G0 PHASE; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES;

EID: 81055127017     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0498     Document Type: Article

References (31)

1. Chaffer C L, Weinberg R A. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
2. Deng X, Ewton D Z, Friedman E. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by decreasing ROS levels. Cancer Res 2009;69:3317-24.
3. Coller H, Sang L, Roberts J M. A new description of cellular quiescence. PLoS Biol 2006;4:329-49.
4. Jin K, Ewton D, Park S, Hu J, Friedman E. Mirk regulates the exit of colon cancer cells from quiescence. J Biol Chem 2009;284:22916-25.
5. Hu J, Friedman E. Depleting Mirk kinase increases cisplatin toxicity in ovarian cancer cells. Genes Cancer 2010;1:803-11.
6. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 2006;10:241-52. (Pubitemid 44311067)
7. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007;1773:1095-1106.
8. Kim M, Gallick G. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 2008;14:1284-85. (Pubitemid 351413904)
9. Olive K P, Jacobetz M A, Davidson C J, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
10. Lee K, Deng X, Friedman E. Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. Cancer Res 2000;60:3631-37. (Pubitemid 30482186)
11. de Magalhães J, Chainiaux F, Remacle J, Toussaint O. Stress-induced premature senescence in BJ and hTERT-BJ1 human foreskin fibroblasts. FEBS Lett 2002;523:157-62.
12. Jin K, Park S-J, Ewton D, Friedman E. The survival kinase Mirk/dyrk1B is a downstream effector of oncogenic K-ras. Cancer Res 2007:67:7247-55. (Pubitemid 47206553)
13. Dimri G, Campisi J. Molecular and cell biology of replicative senescence. Cold Spring Harb Symp Quant Biol 1994;59:67-73.
14. Amaravadi R K. Autophagy-induced tumor dormancy in ovarian cancer. J Clin Investigation 2008;118:3837-40.
15. Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, et al. Cell cycle effects of gemcitabine. Int J Cancer 2001;93:401-8. (Pubitemid 32592060)
16. Morgan M A, Parsels L A, Parsels J D, Mesiwala A K, Maybaum J, Lawrence T S. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005;65:6835-42. (Pubitemid 41060722)
17. Hu J, Nakhla H, Friedman E. Mirk/dyrk1B and p130/Rb2 mediate quiescence in ovarian cancer cells. Int J Cancer 2011;129:307-18.
18. Zou Y, Ewton D, Deng D, Mercer S, Friedman E. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem 2004;279:27790-98. (Pubitemid 38812621)
19. Deng X, Ewton D Z, Li S, Naqvi A, Mercer S E, Landas S, et al. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. Cancer Res 2006;66:4149-58.
20. Janumyan Y, Cui Q, Yan L, Sansam C G, Vanlentin M, Yang E. G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation. J Biol Chem 2008;283:34108-20.
21. Litovchick L, Florens L A, Swanson S K, WashburnMP, DeCaprio J A. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev 2011;25:801-13.
22. Karhu R, Mahlamaki E, Kallioniemi A. Pancreatic adenocarcinoma - genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer 2006;45:721-30.
23. Kuuselo R, Savinainen K, Azorsa D O, Basu G D, Karhu R, Tuzmen S, et al. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res 2007;67:1943-49. (Pubitemid 46424210)
24. Mercer S, Friedman E. Mirk/Dyrk1B: a multifunctional dual-specificity kinase involved in growth arrest, differentiation and cell survival. Cell Biochem Biophys 2006;45:303-15. (Pubitemid 44127946)
25. BonnerWM, Redon C E, Dickey J S, Nakamura A J, Sedelnikova O A, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer 2008;8:957-67.
26. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007;6:1239-48. (Pubitemid 46711987)
27. Karnitz L M, Flatten K S, Wagner J M, Loegering D, Hackbarth J S, Arlander S J H, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 2005;68:1636-44. (Pubitemid 41654347)
28. Azorsa D O, Gonzales I M, Basu G D, Choudhary A, Arora S, Bisanz K M, et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 2009;7:43.
29. Deng X, Mercer S E, Shah S, Ewton D Z, Friedman E. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B Kinase. J Biol Chem 2004;279:22498-504. (Pubitemid 38679449)
30. Leder S, Czajkowska H, Maenz B, de Graaf K, Barthel A, Joost H-G, et al. Alternative splicing variants of the protein kinase DYRK1B exhibit distinct patterns of expression and functional properties. Biochem J 2003;372:881-8. (Pubitemid 36760401)
31. Becker W, Friedman E. Dyrk1b, UCSD-Nature Molecule Pages 2008: doi:10.1038/mp.a000797.01.